Drug Database
Back to search

United States· US:0131-2479_51a12988-3e4b-c52b-e063-6394a90a7415

Vimpat

A lacosamide product containing lacosamide, registered in United States by UCB, Inc.. The same ATC class is registered in 18 of our 19 countries.

ATC N03AX18US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedVimpatATCN03AX18REGISTER NO.US:0131-2479_51a12988…PACKS LISTED6CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lacosamideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lacosamide is registered in 18 of 19 countries.

Countries holding a registration under ATC N03AX18 (lacosamide), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 10 of them publish a price we can compare per daily dose
Search lacosamide products by name

Lacosamide · ATC N03AX18

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lacosamide costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.48 in United States to $3.11 in Switzerland — a ×6.4 gap.

  • United States: $0.48 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Lacosamide · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$3.11
  • IT Italy$3.06
  • FR France$1.49
  • US United States$0.48 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
LACOSAMIDE
Manufacturer
UCB, Inc.
Country
United States (US)
ATC code
N03AX18
ATC class
Lacosamide
Defined daily dose
0.3 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 6

  • ndc11
    0131247935
    60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0131-2479-35)
  • ndc11
    0131247960
    6 BLISTER PACK in 1 CARTON (0131-2479-60) / 10 TABLET, FILM COATED in 1 BLISTER PACK
  • ndc11
    0131247999
    1 BLISTER PACK in 1 CARTON (0131-2479-99) / 14 TABLET, FILM COATED in 1 BLISTER PACK
  • ndc11
    0131-2479-35
  • ndc11
    0131-2479-60
  • ndc11
    0131-2479-99

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

62 interactions on record for lacosamide.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lacosamide against other medicinesHow interaction checks work

Lacosamide · interactions on record

62 records

  • 5 severe
  • 32 moderate

Most severe, free to view

  • DolasetronA04AA04severe
  • CeritinibL01ED02severe
  • CeritinibL01XE28severe
  • SiponimodL04AA42severe

25 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lacosamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lacosamide products

Authorised across Europe · EMA

The same active substance is authorised in 31 EEA countries. Names it is sold under:

  • Austria · Lacopat, Lacopat Packung Zur Behandlungseinleitung
  • Belgium · Lacosamid Hikma, Lacosamide Eg
  • Bulgaria · Канилад, Лакозамид Гриндекс
  • Cyprus · Kanilad, Lacosadel
  • Czechia · Arkvimma, Kanilad
  • Germany · Kanilad, Lackepila
  • Denmark · 200 mg, Lacosamid Opko Health Spain
  • Estonia · Kanilad, Lacosamide Alembic
  • Spain · Balmid, Kanilad
  • Finland · Lacosamide Fresenius Kabi, Lacosamide Grindeks
  • France · Lacosamide Arrow, Lacosamide Biogaran
  • United Kingdom (Northern Ireland) · Lacosamide, Lacosamide Amarox
  • Greece · Anlamyl, Josamec
  • Croatia · Kanilad, Lacosamide Grindeks
  • Hungary · Anlamyl, Arkvimma
  • Ireland · Lacosamide Ascend, Lacosamide Fresenius Kabi
  • Iceland · Josamec, Lacosamide Accord
  • Italy · Lacosamide Aurobindo, Lacosamide Doc
  • Liechtenstein · Lacosamid Fresenius Kabi, Lacosamide Accord
  • Lithuania · Lacosamide Fresenius Kabi, Lacosamide Grindeks
  • Luxembourg · Lacosamide Eg
  • Latvia · Kanilad, Lacosamide Fresenius Kabi
  • Malta · Anlamyl, Kanilad
  • Netherlands · Cosim, Lacosamide Amarox
  • Norway · Lacosamide Accord, Lacosamide Fresenius Kabi
  • Poland · Arkvimma, Epilantin
  • Portugal · Lacosamida Alter, Lacosamida Aristo
  • Romania · Lacosamidă Teva
  • Sweden · Lacomed, Lacosamide 1a Farma
  • Slovenia · Lacosabil, Lacosamide Grindeks
  • Slovakia · Arkvimma, Kanilad

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ca1a6914-abb6-4fd6-8ff5-11b68abeb526
GET /v1/drugs/ca1a6914-abb6-4fd6-8ff5-11b68abeb526?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "150",
  "substance": "LACOSAMIDE",
  "productndc": "0131-2479",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": "CV",
  "strength_unit": "mg/1",
  "application_number": "NDA022253",
  "marketing_category": "NDA"
}
API referenceMCP serverPlans

See everything about lacosamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console